News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Drew Weismann Speaks on the Future of mRNA Technology in Bloomberg’s “The Big Take” Podcast
Weissman talks about his discovery and the impact of mRNA technology on the development of therapies for flu, cancer and rare genetic diseases.
Penn Dental Medicine Researchers Discover Potential Peripheral Nerve Injury Treatment
In their research, the team used SIS stem cells derived from gingival tissue to treat transected facial nerve and sciatic nerve crush injuries in rats.
PCI Team Member and Penn Medicine Featured in Washington Post
Carter Caldwell, Director of the Penn Medicine Co-Investment Program, was featured in the Washington Post’s Medical Mysteries column which described his journey following life-changing brain surgery.
Penn ranks #5 for undergraduate founders and #6 for graduate founders in Pitchbook Data’s ‘Top 100 colleges ranked by startup founders’
Penn ranked #5 for undergraduate founders and #6 for graduate founders. It also ranked #4 for female undergraduate founders and #5 for female graduate founders.
Penn Medicine and Candel Therapeutics partner to pursue potential solid tumor CAR-T cell therapy
The University of Pennsylvania’s Center for Cellular Immunotherapies, led by cell therapy pioneer Dr. Carl June, has entered into a cancer treatment collaboration with Candel Therapeutics.
Jon Epstein Serves as Keynote Speaker at Life Sciences Future – Biopharm, Discusses CAR-T and the Future of Healthcare
During the session, Epstein presented his research, which involves using in vivo CAR-T cell therapy to target cardiac fibrosis. He also discussed the future of healthcare.
Penn spinout and I-Corps participant NeuroFlow raises $25 million growth round, doubles headcount and expands into Center City office
The funding will help Neuroflow, a Philadelphia-based mental health startup, make greater investments in research and development, expand its technology platform and increase headcount.
Philadelphia gene therapy company Passage Bio names former Novartis executive as new CEO
Philadelphia gene therapy company Passage Bio appointed Dr. Will Chou, former Novartis executive, as its new CEO.
Penn Spinout and I-Corps Participant Innervace Raises $40 Million for Parkinson’s Disease Research
The funds will allow Innervace to advance their platform and lead asset in Parkinson’s disease, which aims to reconstruct the neuronal circuitry that is lost in Parkinson's patients.